Habrand J L, Schlienger P, Schwartz L, Pontvert D, Lenir-Cohen-Solal C, Helfre S, Mammar H, Haie-Meder C, Ferrand R, Mazal A
Centre de Protonthérapie d'Orsay, France.
Bull Cancer Radiother. 1996;83 Suppl:207s-11s. doi: 10.1016/0924-4212(96)84914-0.
Proton therapy offers considerable potential advantages in the management of poorly resectable, radio-resistent tumors close to critical anatomical structures. So far over 15,000 patients have been treated worldwide with two major indications: conservative management of ocular melanomas in which local control exceeds 95% at 5 years and curative irradiation of sarcomas at the base of the skull and cervical canal, with a survival rate between 84 and 94% at 5 years. The different protocols tested currently worldwide are discussed.
质子治疗在治疗接近关键解剖结构的难以切除的、抗辐射肿瘤方面具有相当大的潜在优势。到目前为止，全球已有超过15000名患者接受了治疗，主要有两个适应症：眼部黑色素瘤的保守治疗，5年局部控制率超过95%；颅底和颈椎管肉瘤的根治性放疗，5年生存率在84%至94%之间。本文讨论了目前全球正在测试的不同方案。
